85 related articles for article (PubMed ID: 20169940)
21. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
22. Comparison of PathVysion and INFORM fluorescence in situ hybridization kits for assessment of HER-2/neu status in breast carcinoma.
Kakar S; Puangsuvan N; Stevens JM; Serenas R; Mangan G; Sahai S; Mihalov ML
Mol Diagn; 2000 Sep; 5(3):193-7. PubMed ID: 11070153
[TBL] [Abstract][Full Text] [Related]
23. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.
Sauter G; Lee J; Bartlett JM; Slamon DJ; Press MF
J Clin Oncol; 2009 Mar; 27(8):1323-33. PubMed ID: 19204209
[TBL] [Abstract][Full Text] [Related]
24. [Investigation of practical application of fluorescence in situ hybridization (FISH) analysis using microwave irradiation in formalin-fixed, paraffin-embedded tissue sections].
Kurosou K; Murakami S; Jinnai M; Koba H; Imai Y; Yamada T; Ueda Y; Mori Y
Rinsho Byori; 2002 Aug; 50(8):830-4. PubMed ID: 12373822
[TBL] [Abstract][Full Text] [Related]
25. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma.
Bofin AM; Ytterhus B; Martin C; O'Leary JJ; Hagmar BM
Am J Clin Pathol; 2004 Jul; 122(1):110-9. PubMed ID: 15272539
[TBL] [Abstract][Full Text] [Related]
26. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
[TBL] [Abstract][Full Text] [Related]
27. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
Shi Y; Huang W; Tan Y; Jin X; Dua R; Penuel E; Mukherjee A; Sperinde J; Pannu H; Chenna A; DeFazio-Eli L; Pidaparthi S; Badal Y; Wallweber G; Chen L; Williams S; Tahir H; Larson J; Goodman L; Whitcomb J; Petropoulos C; Winslow J
Diagn Mol Pathol; 2009 Mar; 18(1):11-21. PubMed ID: 19214113
[TBL] [Abstract][Full Text] [Related]
28. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
[TBL] [Abstract][Full Text] [Related]
29. Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization.
Ooi A; Kobayashi M; Mai M; Nakanishi I
Lab Invest; 1998 Mar; 78(3):345-51. PubMed ID: 9520947
[TBL] [Abstract][Full Text] [Related]
30. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
31. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis.
Becker KF; Schott C; Hipp S; Metzger V; Porschewski P; Beck R; Nährig J; Becker I; Höfler H
J Pathol; 2007 Feb; 211(3):370-8. PubMed ID: 17133373
[TBL] [Abstract][Full Text] [Related]
32. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
[TBL] [Abstract][Full Text] [Related]
33. Looking for ferns: optimization of digestion pretreatment in fluorescence in situ hybridization (FISH) technique on paraffin-embedded tissues.
Tojo M; Perez-Becerra R; Vazquez-Boquete A; García-Rivero A; García-Caballero T; Forteza J; Fraga M
Diagn Mol Pathol; 2008 Mar; 17(1):59-63. PubMed ID: 18303405
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
[TBL] [Abstract][Full Text] [Related]
35. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R
Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
[TBL] [Abstract][Full Text] [Related]
36. Standardization and optimization of fluorescence in situ hybridization (FISH) for HER-2 assessment in breast cancer: A single center experience.
Bogdanovska-Todorovska M; Petrushevska G; Janevska V; Spasevska L; Kostadinova-Kunovska S
Bosn J Basic Med Sci; 2018 May; 18(2):132-140. PubMed ID: 29389309
[TBL] [Abstract][Full Text] [Related]
37. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival.
Kakar S; Puangsuvan N; Stevens JM; Serenas R; Mangan G; Sahai S; Mihalov ML
Mol Diagn; 2000 Sep; 5(3):199-207. PubMed ID: 11070154
[TBL] [Abstract][Full Text] [Related]
38. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma.
Makretsov N; He M; Hayes M; Chia S; Horsman DE; Sorensen PH; Huntsman DG
Genes Chromosomes Cancer; 2004 Jun; 40(2):152-7. PubMed ID: 15101049
[TBL] [Abstract][Full Text] [Related]
39. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
